Paul Peter Tak, Candel Therapeutics CEO

Us­ing her­pes virus vec­tors, Paul Pe­ter Tak and Carl June team up to solve the CAR-T sol­id tu­mor chal­lenge

Paul Pe­ter Tak’s on­colyt­ic virus start­up is jump­ing head-first in­to a new part­ner­ship, look­ing to tack­le sol­id tu­mor CAR-Ts.

Can­del Ther­a­peu­tics is join­ing forces with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.